The Next Drugs: An Atlantic Policy Update on Biosimilars
June 7, 2017 – Newseum, Knight Broadcast Studio – 8:00-10:00 AM ET
Biosimilars – and the policy and regulatory debates surrounding these complex large-molecule drugs – continue to be a hot topic in Washington. A patent case in front of the Supreme Court and laws making their way through Congress have the potential to change the market and industry.
In conjunction with The Atlantic, The Biosimilars Council will convene key stakeholders to discuss the state of and future for biosimilars. What impact will ongoing regulatory and policy considerations have? What can stakeholders expect when it comes to patents and exclusivity? And what effect will the priorities of leadership in Congress and the Administration have on the industry across the next few years?
If you are not able to join us in person, we encourage you to follow along with the live stream – which can be found below.
Additionally, please consider joining The Biosimilars Council from September 12-13, 2017 at the 2017 AAM Biosimilars Council Conference in Washington, D.C. For more information and to register, visit our event page.
Information on past Next Drugs events from The Biosimilars Council and The Atlantic:
The Next Drugs: The Future for Biosimilars, An Atlantic Policy Briefing(March 15, 2017)
Primary Discussion Topic: New guidelines on naming and interchangeability from the U.S. Food and Drug Administration
The Next Drugs: An Atlantic Policy Briefing on Biosimilars (Dec. 7, 2016)
Primary Discussion Topic: The regulatory framework of biosimilars